Financial Statements and Highlights | Takeda Investor Relations

glasses laying on a book with stock options

Financial Highlights

Loading feed metadata...

Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet

Recent News

Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases

November 27, 2023

Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

November 9, 2023

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

November 8, 2023

Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting

November 7, 2023

Explore

Investor Events

Access our IR events calendar and recaps of past events

Our Pipeline

Learn more about our dynamic and diverse pipeline